Sudan Loganathan
Stock Analyst at Stephens & Co.
(3.66)
# 693
Out of 5,157 analysts
47
Total ratings
52.5%
Success rate
8.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMNM Immunome | Maintains: Overweight | $33 → $30 | $21.86 | +37.24% | 4 | Mar 4, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $95 → $100 | $84.58 | +18.23% | 4 | Mar 2, 2026 | |
| APGE Apogee Therapeutics | Initiates: Overweight | $95 | $75.37 | +26.04% | 1 | Dec 17, 2025 | |
| CADL Candel Therapeutics | Reiterates: Overweight | $15 | $5.11 | +193.54% | 2 | Dec 8, 2025 | |
| PYXS Pyxis Oncology | Maintains: Overweight | $5 → $8 | $1.55 | +416.13% | 2 | Nov 24, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $14 → $15 | $13.83 | +8.46% | 3 | Nov 10, 2025 | |
| DCTH Delcath Systems | Maintains: Overweight | $25 → $18 | $9.37 | +92.10% | 4 | Nov 5, 2025 | |
| CNTA Centessa Pharmaceuticals | Initiates: Overweight | $35 | $27.59 | +26.86% | 1 | Oct 28, 2025 | |
| CCCC C4 Therapeutics | Reiterates: Overweight | $6 | $3.12 | +92.31% | 3 | Sep 22, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | $45 | $34.74 | +29.53% | 3 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $15.90 | +88.68% | 4 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $29 → $60 | $41.29 | +45.31% | 5 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $33 | $24.77 | +33.23% | 2 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $8 | $4.80 | +66.67% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $15 | $5.30 | +183.02% | 2 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $1.21 | +313.22% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $100 | $30.00 | +233.33% | 2 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.73 | +1,056.07% | 1 | May 14, 2024 |
Immunome
Mar 4, 2026
Maintains: Overweight
Price Target: $33 → $30
Current: $21.86
Upside: +37.24%
Kymera Therapeutics
Mar 2, 2026
Maintains: Overweight
Price Target: $95 → $100
Current: $84.58
Upside: +18.23%
Apogee Therapeutics
Dec 17, 2025
Initiates: Overweight
Price Target: $95
Current: $75.37
Upside: +26.04%
Candel Therapeutics
Dec 8, 2025
Reiterates: Overweight
Price Target: $15
Current: $5.11
Upside: +193.54%
Pyxis Oncology
Nov 24, 2025
Maintains: Overweight
Price Target: $5 → $8
Current: $1.55
Upside: +416.13%
Arvinas
Nov 10, 2025
Maintains: Overweight
Price Target: $14 → $15
Current: $13.83
Upside: +8.46%
Delcath Systems
Nov 5, 2025
Maintains: Overweight
Price Target: $25 → $18
Current: $9.37
Upside: +92.10%
Centessa Pharmaceuticals
Oct 28, 2025
Initiates: Overweight
Price Target: $35
Current: $27.59
Upside: +26.86%
C4 Therapeutics
Sep 22, 2025
Reiterates: Overweight
Price Target: $6
Current: $3.12
Upside: +92.31%
IDEAYA Biosciences
Sep 9, 2025
Reiterates: Overweight
Price Target: $45
Current: $34.74
Upside: +29.53%
Jul 10, 2025
Reiterates: Overweight
Price Target: $30
Current: $15.90
Upside: +88.68%
Jun 24, 2025
Upgrades: Overweight
Price Target: $29 → $60
Current: $41.29
Upside: +45.31%
Feb 27, 2025
Reiterates: Overweight
Price Target: $33
Current: $24.77
Upside: +33.23%
Feb 24, 2025
Maintains: Overweight
Price Target: $6 → $8
Current: $4.80
Upside: +66.67%
Jan 22, 2025
Reiterates: Equal-Weight
Price Target: $15
Current: $5.30
Upside: +183.02%
Nov 19, 2024
Reiterates: Overweight
Price Target: $5
Current: $1.21
Upside: +313.22%
May 24, 2024
Reiterates: Overweight
Price Target: $100
Current: $30.00
Upside: +233.33%
May 14, 2024
Initiates: Overweight
Price Target: $20
Current: $1.73
Upside: +1,056.07%